AllSci News
FDA advisory committee recommends AstraZeneca's Truqap for PTEN-deficient prostate cancer
AstraZeneca's Truqap (capivasertib) received a positive recommendation from the US FDA's Oncologic Drugs Advisory Committee (ODAC) for use in patients with...
Skyrizi combo doubles remission rates in refractory Crohn's disease, accelerating Phase III development
During AbbVie's Q1 2026 earnings conference call, held April 29, 2026, the single most consequential pipeline signal was the decision to accelerate Phase...
Novartis Q1'26 Earnings Call: Remibrutinib's MS readout key near-term growth determinant
During its Q1 2026 earnings conference call, held April 28, 2026, Novartis signaled that summer readouts for remibrutinib in relapsing multiple sclerosis...
Adial Pharmaceuticals’ AD04 5-HT3 antagonist pursues FDA National Priority Voucher for alcohol use disorder
Adial Pharmaceuticals (Nasdaq: ADIL), a clinical-stage biopharmaceutical company headquartered in Glen Allen, Virginia, announced submission of an application for consideration under the…
OSR Holdings hands VEGF cancer vaccine to largest shareholder BCM Europe for up to USD 815m milestones
OSR Holdings (NASDAQ: OSRH) has entered a definitive global exclusive license agreement with BCM Europe AG (BCME) covering VXM01, a Phase 3-ready oral...
Johnson & Johnson discontinues JNJ-90014496 CAR-T programs in large B-cell lymphoma
Johnson & Johnson has announced the discontinuation of two investigational CAR-T cell programs in large B-cell lymphoma, citing portfolio priorities and its...
Kytopen, T-CURX, and Fraunhofer IZI establish cell therapy center of excellence for non-viral manufacturing
Cambridge, Massachusetts-based Kytopen Corp., Würzburg-based T-CURX GmbH, and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Würzburg and Leipzig, Germany,…
Greywolf and Genomics partner to develop first-in-class ERAP autoimmune disease treatments
UK-based Greywolf Therapeutics and Genomics have announced a strategic research collaboration to apply large-scale human genetic data to the development of ERAP…
European Commission approves Norgine’s Xolremdi for WHIM syndrome treatment in EU
Norgine announced that the European Commission has granted marketing authorization for Xolremdi (mavorixafor) for WHIM syndrome, making it the first therapy authorized…
Can-Fite's namodenoson shows durable disease control in Phase IIa advanced pancreatic cancer trial
Can-Fite BioPharma (NYSE American: CANF) reported Phase 2a data for namodenoson in advanced pancreatic adenocarcinoma showing stable disease in more than...
Cadrenal's CAD-1005 advances to Phase III trial for heparin-induced thrombocytopenia treatment
Cadrenal Therapeutics (Nasdaq: CVKD) announced that it has completed an End-of-Phase 2 meeting with the FDA for CAD-1005, its investigational...
UNC Chapel Hill receives USD 1.1m NIH grant for HIV and contraception prevention implant
The University of North Carolina at Chapel Hill has received USD 1.1 million in first-year funding from the National Institute of Allergy and Infectious...
University of Southern California receives USD 1.26m NIEHS grant for PFAS metabolic disease research
The University of Southern California has received an NIEHS PFAS grant totaling USD 1,256,897 in first-year funding through the National Institute of...
Sanford Burnham Prebys receives USD 3.86m NIH grant for NTR1 pain management program
Sanford Burnham Prebys Medical Discovery Institute has received a USD 3.86 million UG3 cooperative agreement from the National Institute of Neurological...
Yale University receives USD 1.38m NIH grant for CRISPR-based Alzheimer's tau therapy
Yale University has received a USD 1.38 million NIH cooperative agreement from the National Institute of Neurological Disorders and Stroke to develop a...
The AllSci Brief
Systematic R&D and deal news. Daily.